Fig. 1 (abstract P364).From: 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part TwoIn vivo anti-tumor activity of JNJ-283 in human PD-1 knock-in mice implanted with MC38 tumorsBack to article page